Sucampo's (SCMP) Rescula Faces Generic Challenge, But It's Not a Factor - Maxim Group
Tweet Send to a Friend
Maxim Group analyst Jason Kolbert reiterated a Buy rating and bumped his price target on Sucampo Pharmaceuticals (NASDAQ: SCMP) to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE